Hemosol announces appointment of Edward Lane, C.A. to Board of Directors
August 11 2004 - 5:50PM
PR Newswire (US)
Hemosol announces appointment of Edward Lane, C.A. to Board of
Directors TORONTO, Aug. 11 /PRNewswire-FirstCall/ -- Hemosol Corp.
(TSX: HML; NASDAQ:HMSL) today announced the appointment of Edward
Lane, C.A. to the Board of Directors. Mr. Lane has had a
distinguished business career in the financial, public and
healthcare sectors which includes having served as Chief Financial
Officer of the Canadian Red Cross and later, as President and Chief
Executive Officer of the Canadian Fractionation Corporation. "Ed's
financial and strategic experience is uniquely paired with a deep
operational understanding of the blood and related products
business", said Edward Rygiel, Hemosol's Chairman. "We look forward
to drawing on his experience and insight as we continue to execute
our strategic alliance with ProMetic and the American Red Cross to
extract valuable therapeutic proteins from human blood plasma as
well as our other initiatives to develop new modified blood
proteins - including oxygen therapeutics - to address a broad range
of unmet medical needs." Mr. Lane will replace George Masters who
has stepped down from the Board for personal reasons. "We are very
grateful for the numerous contributions and wise counsel that
George brought to Hemosol, first as President and later, as a
valued member of the Board", added Rygiel. About Hemosol Hemosol is
a biopharmaceutical company focused on the development and
manufacturing of biologics, particularly blood-related proteins.
Hemosol is leveraging its expertise in manufacturing blood proteins
and its state-of-the- art Meadowpine manufacturing facility to seek
additional strategic growth opportunities. Hemosol has a broad
range of novel therapeutic products in development, including
HEMOLINK(TM) (hemoglobin raffimer), an oxygen therapeutic designed
to rapidly and safely improve oxygen delivery via the circulatory
system. Hemosol is also developing next generation oxygen
therapeutics, a hemoglobin-based drug delivery platform to treat
diseases such as hepatitis C and liver cancers, and a cell therapy
program initially directed to the treatment of cancer. For more
information visit Hemosol's website at http://www.hemosol.com/.
Hemosol's common shares are listed on the NASDAQ Stock Market under
the trading symbol "HMSL" and on the Toronto Stock Exchange under
the trading symbol "HML". Certain statements concerning Hemosol's
future prospects are "forward- looking statements" within the
meaning of the United States Private Securities Litigation Reform
Act of 1995 and other applicable securities legislation. There can
be no assurances that future results will be achieved, and actual
results could differ materially from forecasts and estimates.
Important factors that could cause actual results to differ
materially from forecasts and estimates include, but are not
limited to: Hemosol's ability to obtain regulatory approvals for
its products; Hemosol's ability to successfully complete clinical
trials for its products and enter into satisfactory arrangements
for the supply of materials used in its manufacturing operations
and the sale of resulting products to customers; technical,
manufacturing or distribution issues; the competitive environment
for Hemosol's products; the degree of market penetration of
Hemosol's products; Hemosol's ability to obtain sufficient
financing to complete clinical development of its products; and
other factors set forth in filings with Canadian securities
regulatory authorities and the U.S. Securities and Exchange
Commission. These risks and uncertainties, as well as others, are
discussed in greater detail in the filings of Hemosol with Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission. Hemosol makes no commitment to revise or
update any forward-looking statements in order to reflect events or
circumstances after the date any such statement is made.
DATASOURCE: Hemosol Corp. CONTACT: Jason Hogan, Investor &
Media Relations, (416) 361-1331, 800 789 3419, (416) 815-0080 fax,
, http://www.hemosol.com/; Archived images on this organization are
available through CNW E-Pix at http://www.newswire.ca/. Images are
free to members of The Canadian Press. To request a free copy of
this organization's annual report, please go to
http://www.newswire.ca/ and click on reports@cnw.
Copyright